Product Datasheet

EPZ6438

Catalog No. **BP-02307** · CAS **1403254-99-8** · Form **free base** · Physical state **solid** · Color **White to light yellow** · Version **1.0** · Revision **2026-09-10**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Histone Methyltransferase; Apoptosis	**Cancer**

Molecular formula	$C_{34}H_{44}N_4O_4$
Molecular weight	**572.7376**

STRUCTURE



DESCRIPTION

Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, Tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).

BIOLOGICAL ACTIVITY

In Vitro

Tazemetostat (EPZ-6438) inhibits multi wild-type and mutant lymphoma cell lines proliferation with IC50s of 0.49 nM-7.6 μM.

In Vivo

Tazemetostat (EPZ-6438; 250 or 500 mg/kg twice daily for 21-28 days) practically eliminates the fast-growing G401 tumors.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Knutson, Sarah K et al. “Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.” Proceedings of the National Academy of Sciences of the United States of America vol. 110,19 (2013): 7922-7.